Additional data from the Phase II trial of MED2002 (Eroxon®), which completed in 2016 and met its primary efficacy endpoint, has been published in Journal of Sexual Medicine. The data re-confirms the product’s market-leading fast onset of action and excellent tolerability profile. In addition, the trial met a number of relevant secondary efficacy endpoints. We continue to view MED2002 (Eroxon®) as a differentiated product with significant commercial potential in both prescriptio
04 Jan 2018
Additional positive data published on MED2002
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Additional positive data published on MED2002
Futura Medical plc (FUM:LON) | 34.4 0.4 3.3% | Mkt Cap: 103.5m
- Published:
04 Jan 2018 -
Author:
Jens Lindqvist -
Pages:
4
Additional data from the Phase II trial of MED2002 (Eroxon®), which completed in 2016 and met its primary efficacy endpoint, has been published in Journal of Sexual Medicine. The data re-confirms the product’s market-leading fast onset of action and excellent tolerability profile. In addition, the trial met a number of relevant secondary efficacy endpoints. We continue to view MED2002 (Eroxon®) as a differentiated product with significant commercial potential in both prescriptio